Making a case for del(1p) as a high-risk abnormality in multiple myeloma

被引：1
|
作者：
Schmidt, Timothy M. M. [1 ,2 ]
机构：
[1] Univ Wisconsin, Carbone Canc Ctr, Madison, WI USA
[2] 600 Highland Ave,K6-544 MC 5669 Clin Sci Ctr, Madison, WI 53792 USA
来源：
CANCER | 2023年 / 129卷 / 16期
关键词：
PROGNOSTIC-FACTOR; DELETIONS; THERAPY; CDKN2C; GENES; 1P;
D O I：
10.1002/cncr.34893
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：2450 / 2452
页数：3
相关论文
共 50 条
  • [21] Identification of characteristic and prognostic values of chromosome 1p abnormality by multi-gene fluorescence in situ hybridization in multiple myeloma
    F Li
    L Hu
    Y Xu
    Z Li
    S Yi
    Z Gu
    C Li
    M Hao
    K Ru
    F Zhan
    A Zetterberg
    W Yuan
    T Cheng
    L Qiu
    Leukemia, 2016, 30 : 1197 - 1201
  • [22] Identification of characteristic and prognostic values of chromosome 1p abnormality by multi-gene fluorescence in situ hybridization in multiple myeloma
    Li, F.
    Hu, L.
    Xu, Y.
    Li, Z.
    Yi, S.
    Gu, Z.
    Li, C.
    Hao, M.
    Ru, K.
    Zhan, F.
    Zetterberg, A.
    Yuan, W.
    Cheng, T.
    Qiu, L.
    LEUKEMIA, 2016, 30 (05) : 1197 - 1201
  • [23] Current approaches to management of high-risk multiple myeloma
    Goldman-Mazur, Sarah
    Kumar, Shaji K.
    AMERICAN JOURNAL OF HEMATOLOGY, 2021, 96 (07) : 854 - 871
  • [24] A gene expression signature for high-risk multiple myeloma
    R Kuiper
    A Broyl
    Y de Knegt
    M H van Vliet
    E H van Beers
    B van der Holt
    L el Jarari
    G Mulligan
    W Gregory
    G Morgan
    H Goldschmidt
    H M Lokhorst
    M van Duin
    P Sonneveld
    Leukemia, 2012, 26 : 2406 - 2413
  • [25] Should high-risk smouldering multiple myeloma be treated?
    Richard, Shambavi
    Jagannath, Sundar
    Boccadoro, Mario
    Mina, Roberto
    LANCET HAEMATOLOGY, 2020, 7 (01): : E15 - E16
  • [26] Frontline Treatment for High-Risk Multiple Myeloma: Personalized?
    Usmani, Saad
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S89 - S89
  • [27] A gene expression signature for high-risk multiple myeloma
    Kuiper, R.
    Broyl, A.
    de Knegt, Y.
    van Vliet, M. H.
    van Beers, E. H.
    van der Holt, B.
    el Jarari, L.
    Mulligan, G.
    Gregory, W.
    Morgan, G.
    Goldschmidt, H.
    Lokhorst, H. M.
    van Duin, M.
    Sonneveld, P.
    LEUKEMIA, 2012, 26 (11) : 2406 - 2413
  • [28] Crowdsourcing a High-Risk Classifier for Multiple Myeloma Patients
    Dervan, Andrew P.
    Mason, Michael
    Towfic, Fadi
    Amatangelo, Michael
    Auclair, Daniel
    Bassett, Douglas
    Dai, Hongyue
    Dalton, William S.
    Danziger, Samuel
    Flynt, Erin
    Goldschmidt, Hartmut
    Guinney, Justin
    Hose, Dirk
    Mavrommatis, Konstantimos
    Morgan, Gareth J.
    Munshi, Nikhil
    Ratushny, Alexander
    Rozelle, Dan
    Samur, Mehmet Kemal
    Schmitz, Frank
    Shain, Kenneth H.
    Trotter, Matthew
    Walker, Brian A.
    White, Brian S.
    Yu, Thomas
    Thakurta, Anjan
    BLOOD, 2017, 130
  • [29] Dysregulation of Cellular Immunity in High-Risk Multiple Myeloma
    Bekri, Selma
    Katz, Simone
    Kelly, Geoffrey
    Dawson, Travis
    D'Souza, Darwin
    Mason, Michael
    Alloy, Alexandre
    Biswas, Shameek
    Kim-Schulze, Seunghee
    Gnjatic, Sacha
    Parekh, Samir
    Jagannath, Sundar
    Lagana, Alessandro
    Cho, Hearn Jay
    BLOOD, 2023, 142
  • [30] Drug response prediction in high-risk multiple myeloma
    Vangsted, A. J.
    Helm-Petersen, S.
    Cowland, J. B.
    Jensen, P. B.
    Gimsing, P.
    Barlogie, B.
    Knudsen, S.
    GENE, 2018, 644 : 80 - 86
12345